von Willebrand factor binding to myosin assists in coagulation.

von Willebrand factor (VWF) binds to platelets and collagen as a means of facilitating coagulation at sites of injury. Recent evidence has shown that myosin can serve as a surface for thrombin generation and binds to activated factor V and factor X. We studied whether VWF can also bind myosin as a means of bringing factor VIII (FVIII) to sites of clot formation. A myosin-binding assay was developed using skeletal muscle myosin to measure VWF binding, and plasma-derived and recombinant VWF containing molecular disruptions at key VWF sites were tested. Competition assays were performed using anti-VWF antibodies. FVIII binding to myosin was measured using a chromogenic FVIII substrate. Thrombin generation was measured using a fluorogenic substrate with and without myosin. Wild-type recombinant VWF and human plasma VWF from healthy controls bound myosin, whereas plasma lacking VWF exhibited no detectable myosin binding. Binding was multimer dependent and blocked by anti-VWF A1 domain antibodies or A1 domain VWF variants. The specific residues involved in myosin binding were similar, but not identical, to those required for collagen IV binding. FVIII did not bind myosin directly, but FVIII activity was detected when VWF and FVIII were bound to myosin. Myosin enhanced thrombin generation in platelet-poor plasma, although no difference was detected with the addition of myosin to platelet-rich plasma. Myosin may help to facilitate delivery of FVIII to sites of injury and indirectly accelerate thrombin generation by providing a surface for VWF binding in the setting of trauma and myosin exposure.

[1]  A. Sauaia,et al.  Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects. , 2019, Shock.

[2]  A. Sauaia,et al.  Rapid Communication: Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects. , 2019, Shock.

[3]  T. Springer,et al.  The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis. , 2019, Blood.

[4]  G. E. Gilbert,et al.  The evolving understanding of factor VIII binding sites and implications for the treatment of hemophilia A. , 2019, Blood reviews.

[5]  W. H. Baldwin,et al.  A microengineered vascularized bleeding model that integrates the principal components of hemostasis , 2018, Nature Communications.

[6]  O. McCarty,et al.  Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. , 2016, Blood.

[7]  D. Bellissimo,et al.  Crucial role for the VWF A1 domain in binding to type IV collagen. , 2015, Blood.

[8]  A. Huber,et al.  Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[9]  D. Willbold,et al.  Kinetic Titration Series with Biolayer Interferometry , 2014, PloS one.

[10]  R. Schneppenheim,et al.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[11]  T. Walz,et al.  Sequence and structure relationships within von Willebrand factor. , 2012, Blood.

[12]  D. Bellissimo,et al.  Critical von Willebrand factor A1 domain residues influence type VI collagen binding , 2012, Journal of thrombosis and haemostasis : JTH.

[13]  E. Favaloro,et al.  Differential sensitivity of von Willebrand factor (VWF) ‘activity’ assays to large and small VWF molecular weight forms: a cross‐laboratory study comparing ristocetin cofactor, collagen‐binding and mAb‐based assays , 2012, Journal of thrombosis and haemostasis : JTH.

[14]  P. Mannucci,et al.  Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients , 2012, Journal of thrombosis and haemostasis : JTH.

[15]  R. Montgomery,et al.  Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. , 2010, Blood.

[16]  P. Monahan,et al.  Abnormal hemostasis in a knock‐in mouse carrying a variant of factor IX with impaired binding to collagen type IV , 2009, Journal of thrombosis and haemostasis : JTH.

[17]  J. Scott,et al.  Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function , 2009, Journal of thrombosis and haemostasis : JTH.

[18]  B. Yawn,et al.  von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA) 1 , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  R. Romijn,et al.  von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen , 2006, Journal of thrombosis and haemostasis : JTH.

[20]  B. Binder,et al.  Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. , 2006, JAMA.

[21]  M. Crúz,et al.  The interaction of von Willebrand factor‐A1 domain with collagen: mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen , 2006, Journal of thrombosis and haemostasis : JTH.

[22]  Y. Kawai,et al.  The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF. , 2002, Blood.

[23]  J. Goudemand,et al.  The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. , 2001, Blood.

[24]  T. Matsushita,et al.  Localization of von Willebrand Factor-binding Sites for Platelet Glycoprotein Ib and Botrocetin by Charged-to-Alanine Scanning Mutagenesis* , 2000, The Journal of Biological Chemistry.

[25]  D. Erie,et al.  Human Factor IX Binds to Specific Sites on the Collagenous Domain of Collagen IV* , 1997, The Journal of Biological Chemistry.

[26]  H. Gralnick,et al.  A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected]. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Rand,et al.  150-kD von Willebrand factor binding protein extracted from human vascular subendothelium is type VI collagen. , 1991, The Journal of clinical investigation.

[28]  J. McPherson,et al.  Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. , 1987, The Journal of biological chemistry.

[29]  K. Titani,et al.  von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. , 1986, The Journal of biological chemistry.